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A B S T R A C T
A growing number of organisations have become involved
in the development of guidelines for infectious diseases (ID).
The degree of acceptation of guidelines varies from one
country to another. Some of these national differences are
determining the practices of prescribing antibiotics, and
infection control both in hospitals and in the community.
This review provides updated information on ID guideline
programmes, in particular on the topic of antimicrobial
therapy. It is aimed at clinicians, both in their role as care
providers and as designers of local antibiotic guidelines
(antibiotic booklets). Definitions are given and the process
of development is discussed. International and national ID
guideline programmes in the English language are present-
ed. Many URLs provide access to the different websites
where most guidelines can be downloaded free of charge.
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I N T R O D U C T I O N
The phenomenon of guidelines in healthcare runs parallel
with the evolution in medicine from experience-based
medicine to evidence-based medicine (EBM).1 The need
for a guide for preventive, diagnostic, therapeutic and/or
organisational procedures has been apparent since the
last quarter of the past century. A growing number of
organisations have become involved in the development
of guidelines for infectious diseases (ID), in particular on
the topic of antimicrobial therapy and infection control. A
general review of evidence-based guideline development
in ID was published by Peetermans and Ramaekers in
this journal in 2002.2 They concluded that ID guidelines
must meet the international standards of guideline quality
but, most importantly, they also require the integration of
local epidemiology and resistance data. 
The degree of acceptation of guidelines varies from one
country to another. Italian physicians perceive practice
guidelines as externally imposed and cost-containment
tools rather than decision-supporting tools.3 On the other
hand, according to a survey carried out among Dutch
physicians,4 it appears that more than 75% of the responders
do not or only sometimes dislike guidelines. The minor
aversion appeared to depend on organisational and financial
restrictions, legal aspects, and insufficient support from
hospital management. National differences in acceptance
of guidelines have an impact on the prescribing practices
of antibiotics. Antibiotic use in the Netherlands is among
the lowest in Europe.5 In a survey on antibiotic control
measures, local antibiotic guidelines were present in 95%
of Dutch secondary care hospitals. However, in the
process of development, antibiotic committees made use of
international and national guidelines for local guidelines
in only 36 and 19%, respectively.6 There is a clear need
for more information. The aim of the present paper is to
provide an update on international and national guide-
lines on infectious diseases. In the section on guideline
programmes, many links provide access to the websites
where most guidelines can be downloaded free of charge.
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D I S E A S E S
The main motive for the development of clinical practice
guidelines is to increase the quality of care. Guidelines
aim to be a support for clinical decision-making, decrease
the unwanted diversity of treatment procedures, and
increase insight into clinical practice (for both the physician
and the patient). Some bodies aim to achieve a broader
goal than quality alone. Thus the Infectious Diseases
Society of America (IDSA) maintains that guidelines
must also promote cost-effectiveness. Guidelines can also
serve as an educational tool and last but not least, for
infectious diseases, the control of microbial resistance
has become an important goal of guidelines.
D E F I N I T I O N S
There is a large diversity in the terminology of guidelines,
leading to confusion by users who are not familiar with the
jargon. Table 1 shows an actualised, referenced selection
of authoritative definitions of terms related to guidelines
on infectious diseases and antimicrobial therapy.
Guidelines can be international, national or local.
National guidelines can – and must – be translated into
local/regional policies. National guidelines on antimicrobial
therapy can constitute a framework for local hospital
antibiotic policies.7 According to current insights a guide-
line must include more than recommendations only; it
must also include a description of the methodology used
and supporting evidence. The older definition of clinical
practice guidelines ‘A systematically developed statement’8
is now only applicable to that part of the guideline con-
taining the recommendations. Protocols use national
guidelines as a starting point, but formulate more specific
recommendations that should be applied in certain local
healthcare settings. In the development of a protocol,
integrated care pathways are often used. Standards usually
have a more specific goal than guidelines. The concept
‘standards’ as used in English literature refers to minimum
norms which a professional is assumed to satisfy. As a
rule, the preference for and the results of certain inter-
ventions are already known before a standard is created.
Standards therefore leave little room for the physician
who does not want to comply. They can thus also be
called requirements. For example, the Dutch Inspectorate
for Healthcare considers the guidelines of the Working
Party on Infection Prevention (WIP) (see below) to be
professional standards, on which hospital infection control
protocols should be based. The IDSA initially published
quality standards to be applied without controversy in
most hospital settings to review the care of patients with
certain infectious diseases problems.9 Since 2001, however,
Gyssens. International guidelines for infectious diseases.
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Table 1 Definitions of guidelines on infectious diseases
Term Definition Reference
Guideline programme A structured and coordinated programme designed with the specific aim of 11
producing several clinical practice guidelines
Guideline, clinical guideline, A document that includes a set of statements about appropriate healthcare to support 11
clinical practice guideline daily practice, based on evidence and critical appraisal, aimed at the explicit statement of 
good medical practice
Recommendation A systematically developed statement to assist the practitioner in making decisions about 11
appropriate healthcare for specific clinical circumstances 
Standard (quality, Authoritative statements of (1) minimum levels of acceptable performance or results, 8, 12
standard of care) (2) excellent levels of performance or results, or (3) the range of acceptable performance 
or results 
Protocol A programmed and detailed description of a practice policy, with clear, well-defined 11
decisions. Usually description of the process of care taking into account the specific local 
regional/clinical situation. Protocols often contain algorithms
Integrated care pathways Structured multidisciplinary care plans with detailed essential steps in the care of 33
patients with a specific clinical problem 
Antibiotic guide, booklet A local application of (inter)national guidelines on antimicrobial prophylaxis and therapy 34
Formulary, drug list A list of drugs. Can be part of a policy by limitation of the number of drugs listed. 12
Does not contain advice on indications 
Performance measures Methods or instruments to estimate or monitor the extent to which the actions of a 12
healthcare practitioner or provider conform to practice guidelines or standards of 
quality (compliance)
Quality indicator A measurable element of practice performance for which there is evidence or consensus 35
that it can be used to assess, and hence change, the quality of care provided
Review criteria Systematically developed statements that can be used to assess the appropriateness 36
of specific healthcare decisions, services, and outcome
the IDSA no longer produces standards of care; it is stated
that other organisations can adopt or adapt the guidelines of
the IDSA for this purpose.10 The Dutch College of General
Practitioners (NHG) has up to now produced guidelines
which they call ‘standards’, so that this concept has
acquired a different meaning in the Netherlands than in
general literature.11
In the past, there has been an indiscriminate use of various
terms such as formularies, policies, antimicrobial booklets
and guides to describe local guideline documents. To avoid
confusion among users and evaluators, a clear distinction
between formularies and antibiotic booklets should be made.
A formulary is only a list of drugs and does not provide a
judgment of their application (i.e. the indications).12 So
the word ‘formulary’ should not be used for an antibiotic
guide or booklet. A formulary can be part of a chapter, for
instance, or a guideline document. Worldwide, old-fashioned
terms, such as vademecum, blueprint and compendium
are still used to describe national or local consensus
guidelines on antimicrobial therapy, although it is unclear
what the different terms add or stand for.
D E V E L O P M E N T
Appraisal of Guidelines Research and Evaluation (AGREE)
is a valuable checklist that has been developed to evaluate
the quality of a guideline,13 but it can also be used for
design. In this issue of the journal, the application of the
AGREE instrument in the design of the SWAB guidelines
is described in an editorial by the Dutch Working Party
on Antibiotic Policy of the SWAB guideline committee.14
The AGREE instrument was developed through the
cooperation of an international consortium of designers
of guidelines. The instrument comes with a handbook
and can be downloaded from the AGREE website
www.agreecollaboration.org. Information and communi-
cation technology (ICT) is facilitating the process of
guideline development by the consultation of stakeholders
through a closed part of a website. Target users can log in
from anywhere at any desired moment and insert their
comments. A less sophisticated strategy is to post the draft
guidelines on the internet for a period of time and request
(electronic) commentaries. Guidelines can be revised
more regularly, but the frequency is to a certain extent
limited by how often the professionals can incorporate
new material. However, even with these new approaches,
the design phase of an evidence-based guideline can last
one to three years depending upon the complexity of the
subject. For multidisciplinary guidelines, i.e. antimicrobial
therapy, many parties have to be consulted and this causes
extra delay. One consequence of this long development
process can be that the guideline is already out-of-date at
the time it is finished, due to new available knowledge.
Which topics to select? 
In general, clinical practice guidelines are considered use-
ful when physicians are uncertain about the appropriate
treatment for which scientific evidence is available.15 In
infectious diseases there is usually a need for guidelines
for empirical therapy and prophylaxis, and for diagnostics.
In the field of empirical therapy, maximal efficacy of a
blindly chosen broad-spectrum drug has to be balanced
against the danger of selection of antimicrobial resistance.
A topic can be chosen from the most common infectious
diseases, such as respiratory tract or urinary tract infections, or
the most threatening (high morbidity and mortality), such
as bacteraemia. Topics can also be selected about which
there are controversies, such as selective decontamination.
A major reason to develop national guidelines for empirical
therapy is the divergence of national antimicrobial resist-
ance rates from those that support the choice of drugs in
an authoritative international guideline. In connection
with the support needed for implementation, the choice
of a topic is best made in consultation with as large a
group as possible. 
Who should author guidelines on antimicrobial therapy? 
There is a certain paradox in the fact that international
guidelines usually have experts as their authors – therefore
these guidelines have considerable authority. In contrast,
because the users of local guidelines are themselves often
involved at an early stage in the development process, these
guidelines usually enjoy greater support because the providers
have committed themselves at this early stage. An investi-
gation by Grol et al. among Dutch medical specialists
revealed that 80 to 90% appreciated and used the guide-
lines that were produced by their own scientific society in
contrast to 50% for the same guidelines but produced by
the Dutch Institute for Healthcare Improvement.16
D I S T R I B U T I O N  A N D  A V A I L A B I L I T Y
Guidelines used to be distributed as printed matter, either
as articles, a supplement to a medical journal or a book.
Nowadays they are also placed on the internet, allowing
more frequent actualisation. Almost all clinical practice
guidelines can be downloaded free of charge from the
websites of the organisations or the publisher. Many
guidelines are distributed via multiple channels, to reach
a maximum of healthcare workers.9 IDSA guidelines are
published in up to three journals: Clinical Infectious
Diseases and two infection control journals. Since 2003,
the SWAB guidelines are published both in Dutch and in
English. In addition, the complete guideline containing
the literature search and the recommendations can be
downloaded from the SWAB website. Distribution of the
guideline is the first step in its implementation, but this
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is insufficient in practice. Discussions at (consensus)
conferences or approval of the guideline at the general
meeting of the relevant scientific society increases support.
Adherence to the guideline can be increased by decision
aids, summary cards and patient education and information
leaflets. The Dutch College of General Practitioners pro-
vides CME packages for each practice guideline, complete
with assessment and feedback procedures.
I M P L E M E N T A T I O N
Quality is only partially responsible for the successful
application of a guideline. Whether and to what extent a
guideline is followed therefore depends partially on the
evidence presented in support of the recommendations,
but also on the complexity of the requested action, the
skills of, or the changes required in the organisation, and
the clarity of the design.16 A number of steps have been
identified which lead to optimum use of the guidelines.11
No single intervention works in all situations. Most of the
methods of implementation are more or less effective,
depending on the local situation and the presence of
barriers. Education must be followed by interactive educa-
tion, in which the participants can apply the proposed
changes. Feedback alone is not effective, but it is often
crucial at the beginning of the intervention. Face-to-face
instruction (technique of the pharmaceutical industry) is
especially effective when the ‘detailer’ is well-trained and
a relationship based on trust has been established with
the professionals. Interventions which are directed
toward better organisation of care processes and changes
in the culture of institutions, as well as interventions which
attempt to improve care via the patient, have not been
studied often.16 Measures for limitation of the financial
reimbursement for antibiotics have had a significant
effect on the prescription conduct of general practitioners
in Denmark17 and surgeons in Belgian hospitals.18
Recently, the importance of wording the guideline in
precise behavioural terms has been stressed.19
C O N F L I C T S  O F  I N T E R E S T  A N D  
D I S C L A I M E R S
Solid clinical practice guidelines should state possible
conflicts of interest.20 The highest level of evidence for a
guideline is obtained by the most expensive form of
research, the randomised controlled trial. The costs of
such research on antimicrobial drugs can only be met by
means of financial support from major drug companies.
As a result, research scientists acquire bonds not only with
large independent subsidising governmental institutions,
but also with the industry. Recently it was reported that
research that is paid for by the pharmaceutical industry
more often results in a positive report for the drug under
investigation than independent research.21 In addition, a
positive investigation is also published more often (publi-
cation bias). The conflicts of interest of designers of
guidelines on therapy seem to be inevitable. The experts
who are requested to formulate best practice are the same
individuals who conduct sponsored research in the field
in which they excel. There is certainly no reason to reject
guidelines simply because of interests on the part of the
designers. The users of the guideline, however, should
be informed. A formal process built in to guideline
development that forces authors to declare their financial
interests and written declarations of competing interests
was proposed in 2002.22 At present, there are still many
divergent practices. The Dutch Association of Respiratory
Care Physicians (NVALT) gives complete transparency
regarding its sponsors from the (pharmaceutical) industry
on its website. The National Coordinator Infectious
Disease Control (LCI) lists the details of an industry-
sponsored project of the handheld version of the guidelines
on their website. On the website of the Dutch College of
General Practitioners, the NHG, it is difficult to find
information about (governmental) grants for the clinical
practice guidelines. The IDSA guidelines present lists of
authors and their connections with diverse pharmaceutical
companies in the paragraph ‘Disclosure of Financial
Interests’. The Cochrane collaboration www.cochrane.org/
has recently posted an extensive consensus document
on its website which describes its structure, funding and
the conditions for corporate sponsorship of all co-workers
and sponsoring of reviews. Reassurance was sought that
the conclusions of Cochrane reviews are not biased
through the influence of funding by commercial entities
that stand to benefit financially from the results of
reviews. The SWAB policies regarding conflicts of 
interests and governmental sponsorship are clarified on
the website.
Most websites of ID guideline providers present some
form of disclaimer. The Scottish Intercollegiate Guidelines
Network (SIGN) has a document entitled ‘Notes for users’
in which they explain that their guidelines should not be
considered as standards. The WIP guidelines can only be
downloaded after the user has declared that he agrees with
the WIP declining the responsibility for the application of
the guidelines to specific cases. 
E V A L U A T I O N  O F  A  G U I D E L I N E  A N D
I T S  U S E
After the guideline has been developed and implemented,
the degree to which the guideline is used in practice must
be determined, i.e. what are the barriers to adherence.
Gyssens. International guidelines for infectious diseases.
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Barriers effecting physician’s knowledge, attitude and
behaviour have been discussed by Peetermans and
Ramaekers.2 Evaluation of support by (potential) users
can be achieved by means of questionnaires or interviews.
In 2000 and 2002 the SWAB sent a written (anonymous)
questionnaire to antibiotic committees to assess awareness
and support of its guidelines.6,23 In subsequent interviews,
it appeared that systematic use of SWAB guidelines for
the establishment of local antibiotic guidelines (booklets)
is difficult due to the nonstandardised approach and the
rather individualistic operating procedures of the antibiotic
committees. The target group acknowledges the need for
sound national guidelines on infectious diseases; however,
the position of the SWAB guidelines is not always crystal
clear (J. Bos, unpublished data). In reaction, the SWAB
organised a workshop for members of hospital antibiotic
committees in 2004 and is preparing an ICT programme
to make the SWAB guidelines more accessible.
In order to measure whether a guideline has the desired
result in practice, quality indicators must be developed
(table 1). Quality indicators are measurable variables of
care which give a signal about quality based on the guide-
line. One can differentiate between process indicators,
which assess the outcome of medical-specialist care
according to the guideline, and result indicators, which
assess the results of medical-specialist care according to
the guidelines. Process indicators such as the adherence
of physicians to international guidelines have been inves-
tigated frequently. Less is known about the adherence of
specialists to their own guidelines. Audits provide this
type of information.24 In the field of infectious diseases,
the result indicators are given by patient results or micro-
biological results, such as resistance. The Surgical
Prophylaxis and Surveillance project (CHIPS), which
predominantly used audit and feedback, led to the success-
ful implementation of the recommendations from the
national SWAB guideline ‘Perioperative Prophylaxis’. The
fact that the patient result indicator, postoperative wound
infections, remained stable suggests that a restrictive
antibiotic policy, combined with correct timing, is just as
effective as former practices.25
I N F E C T I O U S  D I S E A S E S  G U I D E L I N E S
I N  T H E  E N G L I S H  L A N G U A G E
There are diverse guideline programmes for the field of
infectious diseases in the English language, which make
use of different methods (table 2). 
Infection control
The American Centers for Disease Control (CDC) produces
prevention guidelines. Sources for the CDC guidelines
are variable. Two-thirds of the documents were originally
published as CDC’s Morbidity and Mortality Weekly
Report (MMWR). A steering committee for the CDC
selects documents to be included in the prevention guide-
lines database. The Society for Healthcare Epidemiology
of America (SHEA) develops guidelines for hospital
hygiene, termed position papers. The public part of the
website provides little information on methodology. The
Australian independent advisory body for healthcare, the
National Health and Medical Research Council
(NHMRC), has recently produced an elaborate infection
control guideline for health professionals (table 2). 
Management of infectious diseases 
The IDSA started its programme for guidelines in 1994
with four quality standards. Since 1997, the society has
developed guidelines only according to the method
described in the Guide to the Development of Practice
Guidelines.10 The American Thoracic Society (ATS) 
publishes guidelines in the American Journal of Respiratory
and Critical Care Medicine. These documents are also
available free of charge in PDF format on their website.
The Canadian Medical Association (CMA) has produced
evidence-based guidelines on the topic of infectious diseases,
of which many have been revised recently. Guidelines
published by the Public Health Agency of Canada and
the Canadian Task Force on Preventive Healthcare are
downloadable via CMA infobase.
The SIGN designs guidelines which are methodologically
very strong. Together with the National Institute for
Clinical Excellence (NICE) www.nice.org.uk, SIGN has
developed guidelines for the National Health Services
(NHS) of Scotland and England/Wales, respectively. The
British Thoracic Society (BTS) of respiratory medicine
physicians has issued guidelines on pneumonia. The
guidelines of The British Society for Antimicrobial
Chemotherapy (BSAC) have been published in the
Journal of Antimicrobial Chemotherapy. Draft guidelines
are being issued for open consultation on the BSAC
website. The New Zealand Guidelines Group (NZGG), 
a prominent organisation that develops guidelines
according to evidence-based medicine, has only one topic
in infectious diseases, a national tuberculosis control
guideline (table 2). 
The Cochrane Collaboration www.wileyeurope.com/go/
cochrane provides important building blocks for the
development of guidelines. This is an international non-
profit and independent organisation that involves more
than 10,000 people worldwide. The formal structure of
the Collaboration comprises Collaborative Review Groups
(which produce systematic reviews) and Centres (with
responsibilities that include support for the review
groups within their area of geographical responsibility).
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It systematically publishes and distributes literature sur-
veys of interventions in healthcare. The Cochrane Library
contains more than 50 Cochrane Database Systemic Reviews
on antibiotic prophylaxis or therapy with recent updates.
Many of these reviews highlight the lack of evidence for
antibiotics already introduced in clinical practice and call
for larger, well-designed randomised trials. Since 2003,
the Cochrane Collaboration has commercially marketed
the reviews. Residents in a number of countries get
access for free through a ‘national provision’. There are
also several programmes that provide free access in Latin
America and low-income countries. Abstracts can be
accessed free of charge at www.cochrane.org/reviews. 
Examples of commercial applications of guidelines on
antibiotic therapy are the Sanford Guide and the Johns
Hopkins Guide. Both are written by excellent authors and
contain many up-to-date literature references. However,
neither booklet can be considered as an ‘antibiotic guide
Gyssens. International guidelines for infectious diseases.
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Table 2 Organisations with evidence-based guideline programmes in the field of infectious diseases in the English
language
Name of organisation Product, scope Recent subjects (within the last two years)
Centers for Disease Control (CDC) Guidelines on infection Compendium of animal rabies prevention and control;
www.cdc.gov prevention and immunisations medical examiners, coroners and biological terrorism; 
prevention and control of influenza; diagnosis and management
of food-borne illnesses; prevention of healthcare associated 
pneumonia (2004)
Society for Healthcare Epidemiology Guidelines, position papers Infection control recommendations for patients with cystic 
of America (SHEA) on infection control fibrosis (2003)
www.shea-online.org Preventing nosocomial transmission of multidrug-resistant 
strains of Staphylococcus aureus and Enterococcus (2003)
Public Health Agency of Canada Guidelines on infection Statement on travel, influenza and prevention; update on 
www.phac-aspc.gc.ca/ prevention and meningococcal C conjugate vaccines (2005)
immunisations Statement on bacille Calmette Guérin (BCG) vaccine (2004)
National Health and Medical Guidelines Infection control guidelines for the prevention of transmission
Research Council of Australia of infectious diseases in the healthcare setting (2004)
(NHMRC), www.health.gov.au
Infectious Diseases Society of Guidelines on clinical Management of adults with hospital-acquired, ventilator-
America (IDSA) management of infectious associated, and healthcare-associated pneumonia; diagnosis
www.idsociety.org diseases and treatment of asymptomatic bacteriuria in adults (2005)
Treating opportunistic infections among HIV-infected adults 
and adolescents; outpatient parenteral antimicrobial therapy; 
antimicrobial prophylaxis for surgery; treatment of candidiasis; 
diagnosis and treatment of diabetic foot infections; management
of bacterial meningitis (2004) 
Treatment of tuberculosis (2003)
American Thoracic Society (ATS) Guidelines on management Management of adults with hospital-acquired, ventilator-
www.thoracic.org of chest infections associated, and healthcare-associated pneumonia (2005)
Handheld computer (PDA) Tuberculosis treatment (2003)
programme ATS-CDC-IDSA tuberculosis treatment (2004)
Canadian Medical Association Guidelines on infectious Acute otitis media (revised 2004)
(CMA) Infobase, all Canadian diseases Clinical management of chronic hepatitis B and C (revised
clinical guideline developers Physician summaries 2004)
www.cma.ca Patient guides
Scottish Intercollegiate Guidelines Guidelines on prophylaxis and Diagnosis and management of childhood otitis media in
Network (SIGN) therapy containing: primary care (2003)
www.sign.ac.uk/guidelines patient information leaflets, 
section on implementation and 
audit, quick reference guide
British Thoracic Society (BTS) Guidelines on management of Management of pleural infections in children (2005)
www.brit-thoracic.org.uk chest infections Community-acquired pneumonia (update 2004)
Severe acute respiratory syndrome (2003)
British Society for Antimicrobial Guidelines Guidelines for the prophylaxis and treatment of meticillin
Chemotherapy (BSAC) (methicillin)-resistant Staphylococcus aureus (MRSA)
www.bsac.org.uk infections in the United Kingdom (2005)
Antibiotic treatment of endocarditis in adults (2004) 
New Zealand Guidelines Group Guideline Guidelines for tuberculosis control in New Zealand (2003)
(NZGG), www.nzgg.org.nz
for a local hospital’ as defined in table 1, since they do not
take into account the local epidemiology of the causative
agent, the pattern of sensitivity and the formulary and
policy of the local hospital. The Sanford guide, www.san-
fordguide.com, is a pocket-sized reference book. National
editions attempt to compensate for the differences
between the American and the European culture, and
take into account some national differences in resistance
rates.26,27 Like the Sanford guide, the Johns Hopkins
Guide www.hopkins-abxguide.org can be accessed after
registration or be downloaded in a handheld version.
Views on antibiotic policy can not usually be found in
these booklets. The Sanford and Johns Hopkins guides
list their sponsors on the website. 
N A T I O N A L  G U I D E L I N E  P R O G R A M M E S :
E X A M P L E  O F  T H E  N E T H E R L A N D S
It is important to ensure that in a given country the guide-
lines for one subject for a specific professional group are
attuned to one another. The simultaneous existence of
several national guidelines for one subject in a particular
country can cause the care provider overwork, confusion
and discouragement. Fine tuning is very important.
Ideally all designers of guideline programmes for a particular
disease should cooperate to obtain one set of recommenda-
tions in that country.28 In the Netherlands, there is a long
tradition of guideline development, but it is only recently
that there have been attempts towards systematic collabo-
ration between guideline makers.
Infection control
The WIP issues guidelines for hospitals, nursing homes
and other institutions. These guidelines are written by
experts who are actively involved in the provision of
healthcare. The draft guidelines are submitted to all
members; they are also posted on the website for comment.
If relevant, the comments are incorporated into the last
draft which is presented to the National Health Council
for review. The Dutch Inspectorate of Healthcare (IGZ)
considers the guidelines of the WIP to be professional
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Table 3 Guidelines and programmes in the field of infectious diseases in the Netherlands 
Name of organisation Product, scope Recent subjects (and updates within the last two years)
Working Party on Infection Guidelines on infection Policies on MRSA (2003)
Prevention (WIP), www.wip.nl control for hospitals, policies
National Coordinator Infectious Protocols, practice strategies, Hepatitis A, influenza, meningococcal disease, smallpox 
Disease Control (LCI) guidelines on technical care (2003)
www.infectieziekten.nl Handheld computer (PDA) Adenovirus, aviary influenza, condyloma acuminata, EBV, 
programme genital warts, genital herpes, giardiasis, impetigo, leptospirosis, 
lice, malaria, Mycoplasma pneumoniae, plague, pneumococcal 
disease, rabies, SARS, scarlet fever, syphilis, tetanus, West Nile
virus, yellow fever (2004)
Botulism, Creutzfeldt Jakob, haemorrhagic fever, listeriosis, 
S. aureus, group A streptococci (2005)
Dutch College of General Practice guidelines, summary Acute cough (2004)
Practitioners (NHG) cards, education leaflets for Most ID guidelines are from the 1990s, no recent updates
www.nhg.artsennet.nl patients
Working Party on Antibiotic Policy Guidelines as a framework for Therapy of infective endocarditis (2003)
(SWAB) antibiotic policy committees Therapy of community-acquired pneumonia (2005)
www.swab.nl Treatment of acute diarrhoea (draft 2005)
The Quality Institute for Healthcare Guidelines, summary cards Varicella (2003)




The Quality Institute for Healthcare Draft guideline Guideline on antiretroviral therapy (update 2005)
CBO/Dutch Society of AIDS 
Physicians (NVAB)
www.cbo.nl 
The Quality Institute for Guideline Guideline on diagnostics and treatment of community-
Healthcare CBO/Organisations of acquired pneumonia (2003)
Dutch Medical Specialists 
Dutch Society of Pulmonologists 
(NVALT)
www.cbo.nl
Dutch Society for Dermatology and Guideline, patient brochures Guidelines on sexually transmitted diseases diagnosis and
Venereology (NVDV), www.soa.nl therapy (updated 2003 and 2004)
standards, to which healthcare workers are urged to com-
ply. All guidelines of the WIP are available on the internet
and can be downloaded free of charge. The guidelines on
paper can be requested for a fee. Since 1995, the National
Coordinator of LCI has been responsible for the 39
municipal health services and the national service in the
Netherlands. LCI develops protocols that are endorsed by
the Health Council, i.e. ID guidelines for the community
and coordinates outbreak management. The programme
includes protocols on infectious diseases and practice
strategies. 
Management of infectious diseases
The Dutch Institute for Healthcare Improvement (CBO)
has developed consensus guidelines in the Netherlands.
In the past few years the programme has become more
closely related to the guideline programmes of the scientific
societies. The Order of Medical Specialists involved the
CBO closely in the elaboration of the long-term agreements
project ‘Development and implementation of guidelines
for medical specialists’. In this document, it is established
that the development of guidelines is based on available
evidence that is obtained by systematic searching and is
evaluated according to the principles of evidence-based
medicine (EBRO). EBRO guidelines are developed according
to this specific methodology. An EBRO Platform was
established by the CBO and the Centre of Quality of Care
Research www.wokresearch.nl; in 2003 many Dutch
designers of guideline programmes joined. Together with
a number of organisations from around the world, the
EBRO recently founded a new international organisation
for designers of guidelines, the Guidelines International
Network G-I-N www.guidelines-international.net. The
purpose is to promote cooperation between guideline
organisations that use the AGREE method. The Working
Party on Antibiotic Policy (SWAB) has been part of the
EBRO network since 2003. The SWAB guidelines contain
recommendations for therapy and prophylaxis with
antimicrobial drugs. The principles of diagnostics are
included insofar as they are essential for policy. The
SWAB guidelines programme has been established for
in-hospital use. The target group is the multidisciplinary
antibiotic committee of a hospital which can use the SWAB
guidelines to draw up their local antibiotic booklets and
protocols. The SWAB guidelines differ in this respect from
the CBO guidelines and those of the specialist societies
which are directed toward the individual care provider,
and include other aspects of the treatment of infection.
The SWAB guidelines apply to the Dutch situation and
the (low) resistance patterns in the country. They are
based on published national resistance data and data
from the national surveillance system NethMap
www.swab.nl. Therefore, in many infectious diseases,
choices of antibiotics in guidelines from other countries
may not always be applicable to the Dutch situation.
Besides differences in resistance rates, there are clear
differences in recommendations compared with
American guidelines,29 for example not to treat mild
cases of community-acquired pneumonia empirically due
to the possibility of atypical pathogen infection.30 The
Practice Guidelines of the NHG are guidelines for general
practitioners written by general practitioners. Three practice
guidelines on infectious diseases have been translated
into English.
The Blueprint for Paediatric Antimicrobial Therapy31 is 
a collection of national guidelines of the Division of
Paediatric Infectious Diseases of the Dutch Society for
Infectious Diseases and is actually under revision. 
There are two independent sources of information for
guidelines for antimicrobial drugs: the Netherlands
Drug Bulletin (NDB) (Geneesmiddelenbulletin)
www.geneesmiddelenbulletin.nl and the Farmacothera-
peutisch Kompas (national formulary) www.fk.cvz.nl.
Both strive – for a fraction of the amount used by com-
mercial sources – to provide impartial information about
drugs in the Netherlands. The system of peer review of
the NDB was described in a former issue of this journal.
NDB feels very strongly about its independence.32
Although NDB has a distribution of 50,000, to medical
professionals and even to students, the impact of its 
recommendations has not been studied.
C O N C L U S I O N
Guidelines enhance the quality of medical treatment in
general. Care processes become more transparent and
more easily managed. Infectious diseases guidelines are
useful in clinical practice, for student training and post-
graduate training. Guidelines are also important for
development of quality indicators. Moreover, the process
of the development of guidelines points out the direction
for future scientific research because the gaps in knowledge
and evidence become visible. Guidelines for antimicrobial
therapy can be an important way to limit microbial resist-
ance and to combat the spread of resistance.
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